CN115364140B - 一种泡沫私护免洗清洁护理液及其制备方法 - Google Patents
一种泡沫私护免洗清洁护理液及其制备方法 Download PDFInfo
- Publication number
- CN115364140B CN115364140B CN202211041556.6A CN202211041556A CN115364140B CN 115364140 B CN115364140 B CN 115364140B CN 202211041556 A CN202211041556 A CN 202211041556A CN 115364140 B CN115364140 B CN 115364140B
- Authority
- CN
- China
- Prior art keywords
- foam
- private
- care
- parts
- surfactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000006260 foam Substances 0.000 title claims abstract description 35
- 238000004140 cleaning Methods 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000002994 raw material Substances 0.000 claims abstract description 29
- 229920002527 Glycogen Polymers 0.000 claims abstract description 24
- 229940096919 glycogen Drugs 0.000 claims abstract description 24
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000004094 surface-active agent Substances 0.000 claims abstract description 21
- 239000003974 emollient agent Substances 0.000 claims abstract description 19
- 239000001069 triethyl citrate Substances 0.000 claims abstract description 18
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000013769 triethyl citrate Nutrition 0.000 claims abstract description 18
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 claims abstract description 17
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 claims abstract description 17
- 229930014456 matrine Natural products 0.000 claims abstract description 17
- 239000003002 pH adjusting agent Substances 0.000 claims abstract description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 claims description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 8
- 229940073499 decyl glucoside Drugs 0.000 claims description 8
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 claims description 8
- 229940048848 lauryl glucoside Drugs 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003513 alkali Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000004310 lactic acid Substances 0.000 claims description 5
- 235000014655 lactic acid Nutrition 0.000 claims description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 4
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 4
- 229920000570 polyether Polymers 0.000 claims description 4
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 4
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 4
- -1 myristyl oleyl alcohol Chemical compound 0.000 claims description 3
- 229940055577 oleyl alcohol Drugs 0.000 claims description 3
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 16
- 241000186660 Lactobacillus Species 0.000 abstract description 9
- 239000004480 active ingredient Substances 0.000 abstract description 9
- 229940039696 lactobacillus Drugs 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 6
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 5
- 241000222122 Candida albicans Species 0.000 abstract description 4
- 241000588724 Escherichia coli Species 0.000 abstract description 4
- 229940095731 candida albicans Drugs 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 244000052616 bacterial pathogen Species 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 abstract 1
- 230000000474 nursing effect Effects 0.000 abstract 1
- 210000001215 vagina Anatomy 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000218492 Lactobacillus crispatus Species 0.000 description 3
- 241000186783 Lactobacillus vaginalis Species 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007313 Reproductive Tract Infections Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 208000037009 Vaginitis bacterial Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dispersion Chemistry (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Detergent Compositions (AREA)
- Cosmetics (AREA)
Abstract
本发明涉及一种泡沫私护免洗清洁护理液及其制备方法。所述泡沫私护免洗清洁护理液,包括如下原料:活性成分、丙二醇、表面活性剂、润肤剂和pH调节剂;其中:所述活性成分由糖原、苦参总碱和柠檬酸三乙酯组成。所述泡沫私护免洗清洁护理液,采用糖原、苦参总碱及柠檬酸三乙酯共三种原料组成的抗菌护理活性成分,所述三种原料科学配伍后对于女性私处包括白色念珠菌、大肠杆菌和金黄色葡萄球菌在内的常见致病菌具有显著的抗菌协同作用,且对乳酸杆菌有促进作用,本发明具有极高的使用安全性,能够温和呵护女性私处卫生;所述制备方法仅需将各原料依次混合即可,工艺简单易控,有利于规模化产出。
Description
技术领域
本发明属于消毒技术领域,具体涉及一种泡沫私护免洗清洁护理液及其制备方法。
背景技术
女性阴道是一个复杂的微生态系统,健康育龄女性阴道内以乳杆菌为优势菌,通过竞争性粘附,产生乳酸,细菌素等抗菌物质,防止其他微生物在阴道上皮的定植。阴道中乳杆菌数量的减少或者功能异常都可能引起阴道微生态失衡,从而诱发下生殖道感染,包括细菌性阴道病、真菌感染疾病、性传播疾病等以及炎症的发生。
现有技术公开的大多是采用化学成分杀菌原料和植物来源原料相结合的方式以达到降低皮肤刺激性目的的同时在一定程度上提高抗菌效果,但是这样的组合方式在抗菌性能提升方面非常有限。目前缺乏一种抗菌性能优良、同时具有很好的维持阴道内环境动态平衡、预防和治疗阴道炎症的女性清洁护理产品。
故基于此,提出本发明技术方案。
发明内容
为了解决现有技术存在的问题,本发明提供了一种泡沫私护免洗清洁护理液及其制备方法。所述泡沫私护免洗清洁护理液,采用糖原、苦参总碱及柠檬酸三乙酯共三种原料组成的抗菌护理活性成分,所述三种原料科学配伍后对于女性私处包括白色念珠菌、大肠杆菌和金黄色葡萄球菌在内的常见致病菌具有显著的抗菌协同作用,且对乳酸杆菌有促进作用,本发明具有极高的使用安全性,能够温和呵护女性私处卫生;所述制备方法仅需将各原料依次混合即可,工艺简单易控,有利于规模化产出。
本发明的方案是提供一种泡沫私护免洗清洁护理液,其包括如下原料:活性成分、丙二醇、表面活性剂、润肤剂和pH调节剂;其中:
所述活性成分由糖原、苦参总碱和柠檬酸三乙酯组成。
糖原,是一种由葡萄糖通过α-1,4和α-1,6糖苷键连接而成的多糖,主要存在于骨骼肌和肝脏中。阴道上皮细胞中也聚集有丰富的糖原,当浅层细胞脱落后,糖原在阴道杆菌作用下转变为乳酸,维持阴道的酸性环境(pH≤4.5,多为3.8-4.4),一直其他病原体生长,防止病原菌进入子宫。同时糖原作为乳酸杆菌的能量物质,可以促进乳酸杆菌在阴道内的定植。
苦参总碱,即苦参总生物碱,从苦参根中提取,具有清热、除湿、祛风、杀虫等功效,同事还具有抗菌消炎、抗病毒、抗肿瘤、抗过敏等多种作用。苦参总碱对痢疾杆菌、金黄色葡萄球菌、维白痢沙门氏杆菌菌具有显著的抑制作用,对瑾色毛癣菌等十多种皮肤真菌也有不同程度的抑制作用。苦参总碱对体外细胞培养的上清液和局部炎症渗出液中的TNF-α、IL-6和IL-8菌具有一定的抑制作用。
柠檬酸三乙酯,在美容领域用于治疗皮肤老化,具有一定的抗菌作用,可作为细菌性皮肤感染的活性成分。
发明人发现,以上三种原料之间具有明显的协同作用,将其进行组合,能够使得其抗菌消炎性能大幅提高,能够专门针对女性私处特定部位的抗菌消炎和维持稳态需求,同时具有极高的使用安全性。
优选地,所述的泡沫私护免洗清洁护理液包括如下重量份的原料:糖原0.01~1份、苦参总碱0.2~3份、柠檬酸三乙酯0.01~1份、丙二醇0.8~12份、表面活性剂0.1~5份、润肤剂0.5~5份、pH调节剂0.01~0.3份。
优选地,所述的泡沫私护免洗清洁护理液包括如下重量份的原料:糖原0.5份、苦参总碱1.6份、柠檬酸三乙酯0.5份、丙二醇6份、表面活性剂2.5份、润肤剂2.5份、pH调节剂0.15份。
优选地,所述表面活性剂为癸基葡糖苷或月桂基葡萄糖苷中的一种或两种的组合;所述润肤剂为透明质酸钠、海藻糖或肉豆蔻油醇聚醚乙二酸酯中的一种或任意两种以上的组合;所述pH调节剂为柠檬酸或乳酸中的一种。
优选地,当同时使用所述癸基葡糖苷和所述月桂基葡萄糖苷作为表面活性剂时,所述癸基葡糖苷和所述月桂基葡萄糖苷的重量比为1~2.5:1;当使用任意两种以上原料作为润肤剂时,所述透明质酸钠、所述海藻糖、所述肉豆蔻油醇聚醚乙二酸酯的重量比为0.1~1:1:0.5。
基于相同的技术构思,本发明的再一方案是提供一种泡沫私护免洗清洁护理液的制备方法,所述制备方法包括如下步骤:
(1)将苦参总碱加入丙二醇中混合,溶解均匀后,得到溶液a;
(2)将所述溶液a与水、糖原、柠檬酸三乙酯、表面活性剂、润肤剂和pH调节剂混合搅拌均匀,即得所述泡沫私护免洗清洁护理液。
优选地,在搅拌条件下,向所述溶液a中依次加入糖原、柠檬酸三乙酯、表面活性剂、润肤剂以及pH调节剂,继续搅拌使溶解均匀。
优选地,所述搅拌的转速为45~60r/min。
优选地,所述搅拌均匀后,进行过滤,即得到所述泡沫私护免洗清洁护理液。
本发明的有益效果为:
本发明所述的泡沫私护免洗清洁护理液,采用糖原、苦参总碱及柠檬酸三乙酯共三种原料组成的抗菌护理活性成分,所述三种原料科学配伍后对于女性私处包括白色念珠菌、大肠杆菌和金黄色葡萄球菌在内的常见致病菌具有显著的抗菌协同作用,且对乳酸杆菌有促进作用,本发明具有极高的使用安全性,能够温和呵护女性私处卫生。
本发明所述的泡沫私护免洗清洁护理液的制备方法,仅需将各原料依次混合即可,工艺简单易控,有利于规模化产出。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚,下面将对本发明的技术方案进行详细的描述。显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动的前提下所得到的所有其它实施方式,都属于本发明所保护的范围。
实施例1
本实施例提供一种泡沫私护免洗清洁护理液的制备方法,所用原料如表1所示。
表1原料用量
原料 | 用量 |
糖原 | 0.01g |
苦参总碱 | 0.2g |
柠檬酸三乙酯 | 0.01g |
丙二醇 | 0.8g |
月桂基葡萄糖苷(表面活性剂) | 0.05g |
癸基葡糖苷(表面活性剂) | 0.05g |
海藻糖(润肤剂) | 0.5g |
柠檬酸(pH调节剂) | 0.01g |
水 | 98.37g |
所述制备方包括如下步骤:
(1)将苦参总碱加入丙二醇中混合,溶解均匀后,得到溶液a;
(2)向所述溶液a中依次加入水、糖原、柠檬酸三乙酯、表面活性剂、润肤剂和pH调节剂,于转速为45r/min的条件下混合搅拌均匀,再过滤,即得所述泡沫私护免洗清洁护理液。
实施例2
本实施例提供一种泡沫私护免洗清洁护理液的制备方法,所用原料如表2所示。
表2原料用量
原料 | 用量 |
糖原 | 1g |
苦参总碱 | 3g |
柠檬酸三乙酯 | 1g |
丙二醇 | 12g |
月桂基葡糖苷(表面活性剂) | 5g |
透明质酸钠(润肤剂) | 5g |
柠檬酸(pH调节剂) | 0.3g |
水 | 72.7g |
所述制备方包括如下步骤:
(1)将苦参总碱加入丙二醇中混合,溶解均匀后,得到溶液a;
(2)向所述溶液a中依次加入水、糖原、柠檬酸三乙酯、表面活性剂、润肤剂和pH调节剂,于转速为60r/min的条件下混合搅拌均匀,再过滤,即得所述泡沫私护免洗清洁护理液。
实施例3
本实施例提供一种泡沫私护免洗清洁护理液的制备方法,所用原料如表3所示。
表3原料用量
原料 | 用量 |
糖原 | 0.5g |
苦参总碱 | 1.6g |
柠檬酸三乙酯 | 0.5g |
丙二醇 | 6g |
癸基葡糖苷(表面活性剂) | 2.5g |
肉豆蔻油醇聚醚乙二酸酯(润肤剂) | 2.5g |
乳酸(pH调节剂) | 0.15g |
水 | 86.25g |
所述制备方包括如下步骤:
(1)将苦参总碱加入丙二醇中混合,溶解均匀后,得到溶液a;
(2)向所述溶液a中依次加入水、糖原、柠檬酸三乙酯、表面活性剂、润肤剂和pH调节剂,于转速为50r/min的条件下混合搅拌均匀,再过滤,即得所述泡沫私护免洗清洁护理液。
对比例1
对比例1与实施例3相比不添加糖原,其他操作不变。
对比例2
对比例2与实施例3相比不添加苦参总碱,其他操作不变。
对比例3
对比例3与实施例3相比不添加柠檬酸三乙酯,其他操作不变。
为表明本发明所述泡沫私护免洗清洁护理液的效果,将实施例3、对比例和市售同类产品的杀菌、抑菌效果进行比较,结果如表4所示。
表4杀菌、抑菌效果
注:“+”表示有杀菌、抑菌作用,“+”的数量表示程度;“-”表示没有杀菌、抑菌作用。
由结果可看出,实施例3得到的泡沫私护免洗清洁护理液对大肠杆菌、金黄色葡萄球菌和白色念珠菌具有极好的杀灭效果,而对于优势菌卷曲乳杆菌和阴道乳杆菌也极为友好;同样可看出,由于对比例中的活性成分并不全面,所以其综合灭菌效果远不如实施例3;而市售同类产品不但灭菌效果劣于实施例3,反而也会杀灭优势菌群,综合性能较差。
给予50名志愿者210ml实施例3中制备的泡沫私护免洗清洁护理液,一天一次,连续使用7天,其中20名为妊娠期女性,30名为月经前期女性。测定产品使用前的pH值和使用后的pH值,结果如表5。
表5 pH测定结果
由结果可看出,使用本发明所述泡沫私护免洗清洁护理液后,女性阴道的pH值明显向酸性方向偏移,集中在4~4.4之间,保持一定的酸性环境,对阴道起到自净的作用,不至于发生炎症。
前文提及,由于乳杆菌属优势菌,所以乳杆菌在阴道内的吸附比率亦尤其重要,在使用实施例3所得泡沫私护免洗清洁护理液前、后,卷曲乳杆菌和阴道乳杆菌吸附阴道上皮细胞的比率如表6所示。
由结果可看出,使用后卷曲乳杆菌和阴道乳杆菌的吸附比率明显上升。
以上所述,仅为本发明的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,可轻易想到变化或替换,都应涵盖在本发明的保护范围之内。因此,本发明的保护范围应以所述权利要求的保护范围为准。
Claims (5)
1.一种泡沫私护免洗清洁护理液,其特征在于,由如下重量份的原料组成:糖原0.01~1份、苦参总碱0.2~3份、柠檬酸三乙酯0.01~1份、丙二醇0.8~12份、表面活性剂0.1~5份、润肤剂0.5~5份、pH调节剂0.01~0.3份;
所述表面活性剂为癸基葡糖苷或月桂基葡萄糖苷中的一种或两种的组合;所述润肤剂为透明质酸钠、海藻糖或肉豆蔻油醇聚醚乙二酸酯中的一种;所述pH调节剂为柠檬酸或乳酸中的一种;
当同时使用所述癸基葡糖苷和所述月桂基葡萄糖苷作为表面活性剂时,所述癸基葡糖苷和所述月桂基葡萄糖苷的重量比为1~2.5:1;
所述的泡沫私护免洗清洁护理液的制备方法由如下步骤组成:
(1)将苦参总碱加入丙二醇中混合,溶解均匀后,得到溶液a;
(2)将所述溶液a与水、糖原、柠檬酸三乙酯、表面活性剂、润肤剂和pH调节剂混合搅拌均匀,即得所述泡沫私护免洗清洁护理液。
2.根据权利要求1所述的泡沫私护免洗清洁护理液,其特征在于,由如下重量份的原料组成:糖原0.5份、苦参总碱1.6份、柠檬酸三乙酯0.5份、丙二醇6份、表面活性剂2.5份、润肤剂2.5份、pH调节剂0.15份。
3.根据权利要求1所述的泡沫私护免洗清洁护理液,其特征在于,在搅拌条件下,向所述溶液a中依次加入糖原、柠檬酸三乙酯、表面活性剂、润肤剂以及pH调节剂,继续搅拌使溶解均匀。
4.根据权利要求1所述的泡沫私护免洗清洁护理液,其特征在于,所述搅拌的转速为45~60r/min。
5.根据权利要求1所述的泡沫私护免洗清洁护理液,其特征在于,所述搅拌均匀后,进行过滤,即得到所述泡沫私护免洗清洁护理液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211041556.6A CN115364140B (zh) | 2022-08-29 | 2022-08-29 | 一种泡沫私护免洗清洁护理液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211041556.6A CN115364140B (zh) | 2022-08-29 | 2022-08-29 | 一种泡沫私护免洗清洁护理液及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115364140A CN115364140A (zh) | 2022-11-22 |
CN115364140B true CN115364140B (zh) | 2024-04-19 |
Family
ID=84069316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211041556.6A Active CN115364140B (zh) | 2022-08-29 | 2022-08-29 | 一种泡沫私护免洗清洁护理液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115364140B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111135160A (zh) * | 2020-01-16 | 2020-05-12 | 上海美浮特生物科技有限公司 | 一种泡沫私护免洗抗菌液及其制备方法 |
-
2022
- 2022-08-29 CN CN202211041556.6A patent/CN115364140B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111135160A (zh) * | 2020-01-16 | 2020-05-12 | 上海美浮特生物科技有限公司 | 一种泡沫私护免洗抗菌液及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN115364140A (zh) | 2022-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106334067B (zh) | 含银离子抗菌剂的妇科凝胶、制备方法及应用 | |
CN111135160B (zh) | 一种泡沫私护免洗抗菌液及其制备方法 | |
CN107007515A (zh) | 一种女性私密护理液及其制备方法 | |
KR101651530B1 (ko) | 약초추출물을 이용한 여성청결제 제조방법 | |
CN102028705A (zh) | 一种含生物抑菌成分的妇科用品 | |
CN111449973A (zh) | 一种修复女性阴道微生态平衡的泡沫剂及其制备方法 | |
KR101838404B1 (ko) | 올리고키토산을 유효성분으로 함유하는 여드름 예방 또는 치료용 조성물 | |
KR102069297B1 (ko) | 여성 청결제 조성물 | |
KR102148808B1 (ko) | 천연 항균제를 포함하는 여성청결제 조성물 | |
WO2008104076A1 (en) | Electrocolloidal silver and echinacea root antimicrobial formulation | |
CN114028546A (zh) | 复合多肽杀菌制剂及其制备方法和用途 | |
CN115364140B (zh) | 一种泡沫私护免洗清洁护理液及其制备方法 | |
CN104306853A (zh) | 壳聚糖季铵盐-高良姜精油复合抗菌气雾剂、其制备方法及其应用 | |
CN104069124A (zh) | 用于妇科感染的组合物及制剂 | |
CN114452360B (zh) | 一种小雨燕窝修护滋养凝胶及制备方法 | |
CN110124017A (zh) | 一种抑菌凝胶 | |
KR20230124821A (ko) | 프로바이오틱스 및 금속이온-탄닌산을 포함하는 상처 치유용 조성물 | |
CN109432204B (zh) | 一种银离子喷雾及其制备方法 | |
KR102115668B1 (ko) | 프로바이오틱스 발효물을 포함하는 항여드름 활성을 갖는 화장료 조성물 | |
CN106266037B (zh) | 一种液体凝胶及其制备方法 | |
CN107811958B (zh) | 一种红茶菌发酵润滑液及其制备方法 | |
CN110755630A (zh) | 促进阴道紧致的温敏凝胶、其制备方法及应用 | |
CN107789304B (zh) | 一种玻尿酸润滑液及其制备方法 | |
CN105055439B (zh) | 一种阴道微生态维护、保健和防治制剂及制备方法与应用 | |
KR20200031404A (ko) | 식물성 키토산을 이용한 여성용 청결제 조성물, 이의 제조방법 및 이를 포함하는 여성용 청결제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |